Diagnostic Value of Muscle [11C] PIB-PET in Inclusion Body Myositis

Noto, Yu‐ichi; Kondo, Masaki; Tsuji, Yukiko; Matsushima, Shigenori; Mizuno, Toshiki; Tokuda, Takahiko; Nakagawa, Masanori

doi:10.3389/fneur.2019.01386

Cited by 9 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SUV ratios were significantly higher in all regions assessed in IBM patients compared to PM. Amyloid PET tracer uptake has not been shown to be associated with clinical severity in these studies (160,162).…”

Section: Positron Emission Tomographymentioning

confidence: 88%

See 1 more Smart Citation

Imaging biomarkers in the idiopathic inflammatory myopathies

et al. 2023

View full text Add to dashboard Cite

Idiopathic inflammatory myopathies (IIMs) are a group of acquired muscle diseases with muscle inflammation, weakness, and other extra-muscular manifestations. IIMs can significantly impact the quality of life, and management of IIMs often requires a multi-disciplinary approach. Imaging biomarkers have become an integral part of the management of IIMs. Magnetic resonance imaging (MRI), muscle ultrasound, electrical impedance myography (EIM), and positron emission tomography (PET) are the most widely used imaging technologies in IIMs. They can help make the diagnosis and assess the burden of muscle damage and treatment response. MRI is the most widely used imaging biomarker of IIMs and can assess a large volume of muscle tissue but is limited by availability and cost. Muscle ultrasound and EIM are easy to administer and can even be performed in the clinical setting, but they need further validation. These technologies may complement muscle strength testing and laboratory studies and provide an objective assessment of muscle health in IIMs. Furthermore, this is a rapidly progressing field, and new advances are going to equip care providers with a better objective assessment of IIMS and eventually improve patient management. This review discusses the current state and future direction of imaging biomarkers in IIMs.

show abstract

Section: Positron Emission Tomographymentioning

confidence: 88%

“…Amyloid positron emission tomography (amyloid-PET) has been investigated as a diagnostic tool for IBM and differentiates it from other IIMs such as PM ( 160 – 162 ). These studies have used a relatively small number of patients so far.…”

Section: Positron Emission Tomographymentioning

confidence: 99%

Imaging biomarkers in the idiopathic inflammatory myopathies

et al. 2023

View full text Add to dashboard Cite

show abstract

“…MRI [22][23][24][25][26][27] fast spin-echo T1 imaging has shown prominent muscle atrophy and fat infiltration in a selective distribution with a proximal to distal increasing gradient within a given muscle, and STIR imaging has shown muscle edema often referred to as "inflammation" but whose precise pathologic correlate is unknown. PET imaging with the brain beta-amyloid tracers [ 11 C]PIB-PET 28,29 and [ 18 F]florbetapir 30 for detection of misfolded protein aggregates, noted to have been incorrectly called "beta amyloid", 31 and with the glucose analog 2-deoxy-2-[ 18 F]fluoro-D-glucose (FDG) 32 have also been performed in IBM. Both amyloid and FDG-PET are limited by a lack of specificity for the underlying disease mechanism in IBM.…”

Section: Introductionmentioning

confidence: 99%

Imaging With PET/CT of Diffuse CD8 T-Cell Infiltration of Skeletal Muscle in Patients With Inclusion Body Myositis

Quinn¹,

Moulton²,

Farwell³

et al. 2023

Neurology

View full text Add to dashboard Cite

BackgroundInclusion body myositis (IBM) is a progressive autoimmune skeletal muscle disease in which cytotoxic CD8+ T cells infiltrate muscle and destroy myofibers. IBM has required a muscle biopsy for diagnosis. Here, we administered to IBM patients a novel investigational PET tracer89Zr-Df-crefmirlimab for in vivo imaging of whole body skeletal muscle CD8 T cells. This technology has not previously been applied to patients with autoimmune disease.MethodsFour patients with IBM received89Zr-Df-crefmirlimab followed by PET/CT imaging 24 hours later and results were compared with similar imaging of age-matched patients with cancer. Mean standardized uptake value (SUVmean) was measured for reference tissues using spherical regions of interest (ROIs).Results89Zr-Df-crefmirlimab was safe and well tolerated. PET imaging demonstrated diffusely increased uptake qualitatively and quantitatively in IBM limb musculature. Quantitation of89Zr-Df-crefmirlimab intensity in ROIs demonstrated particularly increased CD8 T cell infiltration in patients with IBM compared to patients with cancer in quadriceps (SUVmean 0.55 vs 0.20, p<0.0001), biceps brachii (0.62 vs 0.26, p<0.0001), triceps (0.61 vs 0.25, p=0.0005) and forearm finger flexors (0.71 vs 0.23, p=0.008).Discussion89Zr-Df-crefmirlimab uptake in IBM patient muscles was present at an intensity greater than the comparator population. The ability to visualize whole body in vivo cytotoxic T cell tissue infiltration in the autoimmune disease IBM may hold utility as a biomarker for diagnosis, disease activity and therapeutic development, and potentially be applicable to other diseases with cytotoxic T cell autoimmunity.

show abstract

“…Fluorine-18 ( 18 F)-labeled fluorodeoxyglucose PET ( 18 FDG-PET) can identify patterns of muscle involvement, and detect concurrent interstitial lung disease and malignancy in IIM via glucose metabolism ( 17 ). 11 C-labeled Pittsburgh compound B-PET (PIB-PET) ( 18 , 19 ) and 18 F-Flobetapir PET identify amyloid-beta in IBM ( 20 ). The use of PET imaging that utilizes a CD8 T lymphocyte-based ligand shows tremendous potential in preliminary studies in IBM ( 21 ).…”

mentioning

confidence: 99%